Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity
Molecules · 2023
DOI: 10.3390/molecules28031325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Yan A Ivanenkov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department, Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Novel variously substituted thiohydantoin-based dispiro-indolinones were prepared using a regio- and diastereoselective synthetic route from 5-arylidene-2-thiohydantoins, isatines, and sarcosine. The obtained molecules were subsequently evaluated in vitro against the cancer cell lines LNCaP, PC3, HCTwt, and HCT(−/−). Several compounds demonstrated a relatively high cytotoxic activity vs. LNCaP cells (IC50 = 1.2–3.5 µM) and a reasonable selectivity index (SI = 3–10). Confocal microscopy revealed that the conjugate of propargyl-substituted dispiro-indolinone with the fluorescent dye Sulfo-Cy5-azide was mainly localized in the cytoplasm of HEK293 cells. P388-inoculated mice and HCT116-xenograft BALB/c nude mice were used to evaluate the anticancer activity of compound 29 in vivo. Particularly, the TGRI value for the P388 model was 93% at the final control timepoint. No mortality was registered among the population up to day 31 of the study. In the HCT116 xenograft model, the compound (170 mg/kg, i.p., o.d., 10 days) provided a T/C ratio close to 60% on day 8 after the treatment was completed. The therapeutic index—estimated as LD50/ED50—for compound 29 in mice was ≥2.5. Molecular docking studies were carried out to predict the possible binding modes of the examined molecules towards MDM2 as the feasible biological target. However, such a mechanism was not confirmed by Western blot data and, apparently, the synthesized compounds have a different mechanism of cytotoxic action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemistry Department, Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia.
- The Federal State Unitary Enterprise Dukhov Automatics Research Institute (VNIIA), 22. ul. Sushchevskaya, 127055 Moscow, Russia.
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, GSP-7, Ulitsa Mklukho-Maklaya 16/10, 17997 Moscow, Russia.
- A. N. Belozersky Research Institute of Physico-Chemical Biology MSU, Leninskye Gory, House 1, Building 40, 119992 Moscow, Russia.
- College of New Materials and Nanotechnologies, National University of Science and Technology MISiS, 119049 Moscow, Russia.
ORCID-Profile: Andrey A Ayginin, Elena K Beloglazkina
Förderung
- Russian Science Foundation
Zitieren
APA
Ivanenkov, Y. A., Kukushkin, M. E., Beloglazkina, A. A., Shafikov, R. R., Barashkin, A. A., Ayginin, A. A., Serebryakova, M. S., Majouga, A. G., Skvortsov, D. A., Tafeenko, V. A., & Beloglazkina, E. K. (2023). Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity. Molecules. https://doi.org/10.3390/molecules28031325
Vancouver
Ivanenkov YA, Kukushkin ME, Beloglazkina AA, Shafikov RR, Barashkin AA, Ayginin AA, et al. Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity. Molecules. 2023. doi:10.3390/molecules28031325
BibTeX
@article{Ivanenkov2023,
author = {Ivanenkov, Yan A and Kukushkin, Maxim E and Beloglazkina, Anastasia A and Shafikov, Radik R and Barashkin, Alexander A and Ayginin, Andrey A and Serebryakova, Marina S and Majouga, Alexander G and Skvortsov, Dmitry A and Tafeenko, Viktor A and Beloglazkina, Elena K},
title = {Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28031325}
}
EUVIMED